ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SAL056

A development code. Also written as “SAL056 56.5μg” and “SAL056 (56.5μg)”.

Its studies are mostly in Osteoporosis, led by Shenzhen Salubris Pharmaceuticals.

Furthest: phase 3, since Jun 11, 20252 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shenzhen Salubris Pharmaceuticals21 open or runningphase 3since Jun 11, 2025Jun 11, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 11, 2025First study: phase 3 study in Postmenopausal Women With OsteoporosisFirst studyNCT07028320 · 493 enrolled · China
  2. May 5, 2026Phase 2 study in Postmenopausal Women With OsteoporosisNCT07579936 · 200 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07579936Postmenopausal Women With Osteoporosis · China2RecruitingJul 30, 2026200
NCT07028320Postmenopausal Women With Osteoporosis · China3CompletedDec 30, 2023493

How it is read

Names in the registry

  • “SAL056 56.5μg”, 1 entry
  • “SAL056 (56.5μg)”, 1 entry

Codes read as this program: SAL056.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.